D
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Price:
48.23
CNY
-1.95%
Market Closed
Market Cap:
¥22.4B
Relative Value
The Relative Value of one Dizal Jiangsu Pharmaceutical Co Ltd stock under the Base Case scenario is 45.99 CNY. Compared to the current market price of 48.23 CNY, Dizal Jiangsu Pharmaceutical Co Ltd is Overvalued by 5%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
45.99
CNY
Overvaluation 5%
D
Multiples Across Competitors
Competitors Multiples
Dizal Jiangsu Pharmaceutical Co Ltd Competitors
Dizal Jiangsu Pharmaceutical Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
D
|
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
|
22.1B CNY | 36.4 | -25.5 | -26.6 | -26.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
388.5B USD | 6.4 | 92.8 | 15.3 | 21.2 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
194.6B USD | 5.3 | 25.2 | 14.6 | 14.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
179.2B USD | 6.1 | 21.1 | 13.1 | 16.2 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117.5B USD | 9.8 | 29.7 | 22.4 | 23.4 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.2B USD | 5.6 | 17.8 | 13.3 | 15.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.1B AUD | 3.1 | 34.1 | 11.3 | 14.2 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
37.5B EUR | 10.6 | 34 | 36.8 | 37.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
